Results 141 to 150 of about 5,430 (178)

Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C. [PDF]

Trop Med Infect Dis
Vieira M, Slovenski I, Large K, Alonso Ruiz A, Moon S.   +4 more
europepmc   +1 more source

Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection.

Cureus
Chowdhury R, Rashid W, Singh T, Rehman A, Daterdiwala NF, Mkosi V, Limbu B, Bukhari SA, Ramadhan A, Dabas MM, Shehryar A, Khan R.   +11 more
europepmc   +1 more source

The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

Journal of Antimicrobial Chemotherapy, 2020
OBJECTIVES: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2.
Saeid Bitaraf, Andrew Hill, Anahita Sadeghi   +2 more
exaly   +3 more sources

Isothermal titration calorimetry and molecular modeling study of the complex formation of daclatasvir by γ-cyclodextrin and trimethyl-β-cyclodextrin

Carbohydrate Polymers, 2023
International audienceThe complex formation between daclatasvir and γ-CD or heptakis(2,3,6-tri-O-methyl)-β-CD (TM-β-CD) was studied by isothermal titration calorimetry and molecular modeling.
Paola Peluso, David Landy, Roberto Dallocchio   +2 more
exaly   +2 more sources

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Lancet, The, 2014
International audienceBackgroundAn unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus ...
Michael P Manns, Stanislas Pol, Ira M Jacobson   +2 more
exaly   +2 more sources

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

Liver International, 2017
International audienceBACKGROUND & AIMS:Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies.
Christophe Hezode, Pascal Lebray, Danielle Botta-Fridlund   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Asunaprevir/daclatasvir

Reactions Weekly, 2016
  +9 more sources